Kala Bio Q1 Loss Narrows, Cash Reserves Stand at $51.25M
Ticker: KALA · Form: 10-Q · Filed: May 14, 2025 · CIK: 1479419
Sentiment: neutral
Topics: 10-Q, financials, biotech, loss
TL;DR
Kala Bio Q1 loss down to $6.4M from $9.4M YoY, still burning cash but has $51M+ in the bank.
AI Summary
Kala Bio, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements show a net loss of $6.41 million for the three months ended March 31, 2025, compared to a net loss of $9.39 million for the same period in 2024. As of March 31, 2025, the company had $51.25 million in cash and cash equivalents.
Why It Matters
The company's ability to manage its losses and maintain sufficient cash reserves is crucial for its ongoing research and development activities and potential future product launches.
Risk Assessment
Risk Level: medium — The company is still operating at a loss, indicating ongoing financial risk and reliance on future funding or product success.
Key Numbers
- $6.41M — Net Loss (Q1 2025) (Reduced loss compared to the prior year period.)
- $9.39M — Net Loss (Q1 2024) (Prior year period comparison for net loss.)
- $51.25M — Cash and Cash Equivalents (Q1 2025) (Liquidity position at the end of the quarter.)
Key Players & Entities
- KALA BIO, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- $6.41 million (dollar_amount) — Net loss for Q1 2025
- $9.39 million (dollar_amount) — Net loss for Q1 2024
- $51.25 million (dollar_amount) — Cash and cash equivalents as of March 31, 2025
FAQ
What was Kala Bio's net loss for the first quarter of 2025?
Kala Bio reported a net loss of $6.41 million for the three months ended March 31, 2025.
How does the Q1 2025 net loss compare to Q1 2024?
The net loss for Q1 2025 was $6.41 million, an improvement from the $9.39 million net loss reported for the same period in 2024.
What was Kala Bio's cash position as of March 31, 2025?
As of March 31, 2025, Kala Bio had $51.25 million in cash and cash equivalents.
What is the company's fiscal year end?
Kala Bio's fiscal year ends on December 31.
What is the company's primary industry classification?
Kala Bio is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding KALA BIO, Inc. (KALA).